Sunday 11 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(208.10%) (139.61%) 6,155.88% 135.25%

+8 more TTM periods

Piotroski F-Score
7 5 8 7
ROA
4.61% 2.64% 3.11% 1.69%
ROIC
18.07% 16.85% 15.96% 9.34%
Return on Tangible Assets
(288.01%) (124.65%) (48.68%) (43.73%)
Average Days of Receivables
78.37 72.51 75.13 78.14
Free Cash Flow per Share
10.29 11.29 10.07 11.13
Free Cash Flow
18,210.00 19,980.00 17,816.00 19,684.00
Other line items

Show all line items

Columns are period end dates